OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

Higher quarterly earnings and unchanged adjusted EBITDA guidance accompanied a lower full-year revenue outlook.

Rhea-AI Summary

OptimizeRx (OPRX) reported third-quarter 2026 revenue of $21.6 million, down year over year, and lowered its full-year revenue outlook.

Revenue fell 17% from $26.1 million. GAAP net income rose to $1.2 million, or $0.06 per diluted share, from $0.8 million, or $0.04. Adjusted EBITDA increased to $6.3 million from $5.1 million. The company now expects 2026 revenue of $87 million to $93 million, with adjusted EBITDA guidance unchanged at $21 million to $25 million.

Nine-month operating cash flow was $12.9 million, versus $11.6 million a year earlier. Cash totaled $22.3 million at September 30, versus $23.4 million at December 31, 2025. Since June 30, the company repaid $9.3 million in debt principal, leaving $10.4 million outstanding. Trailing-12-month net revenue retention fell to 83% from 121%. The company said in-year contracted revenue remained below prior-year levels, while contracted revenue for 2027 was growing.

12 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointQ3 adjusted EBITDA increased to $6.3 million from $5.1 million a year earlier.
• Moderate pointDebt principal repayments since June 30, 2026 totaled $9.3 million, leaving $10.4 million outstanding. 5.3% of market cap
• Moderate pointQ3 total expenses declined to $18.945 million from $23.996 million a year earlier.
• Moderate pointNine-month term-loan proceeds provided $24.298 million, net of issuance costs. 14% of market cap
• Minor pointQ3 GAAP net income rose to $1.2 million from $0.8 million; diluted EPS increased to $0.06 from $0.04.

7 minor points

• Minor pointQ3 non-GAAP net income rose to $3.8 million from $3.1 million; diluted EPS increased to $0.20 from $0.16.
• Minor pointNine-month operating cash flow increased to $12.880 million from $11.627 million a year earlier.
• Minor pointQ3 operating income increased to $2.670 million from $2.071 million a year earlier.
• Minor pointQ3 interest expense fell to $177,000 from $1.154 million a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 adjusted EBITDA guidance remains $21 million to $25 million.
• Minor pointContracted revenue for 2027 is growing, the company said.
• Minor pointA previously significant customer resumed spending in the fourth quarter, the company said.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.2026 revenue guidance lowered to $87 million to $93 million, with in-year contracted revenue below prior-year levels.
• Moderate pointQ3 revenue declined 17% to $21.6 million from $26.1 million a year earlier.
• Moderate pointTrailing-12-month net revenue retention fell to 83% from 121% for periods ended September 30.
• Moderate pointNew term-loan financing added a debt obligation during the first nine months of 2026.
• Minor pointNine-month revenue declined to $61.963 million from $77.190 million a year earlier.

6 minor points

• Minor pointAverage revenue per top-20 pharmaceutical manufacturer fell to $2.504 million from $3.087 million over trailing-12-month periods.
• Minor pointTrailing-12-month revenue per average full-time employee fell to $706,000 from $820,000.
• Minor pointNine-month GAAP results shifted to a $3,000 net loss from $112,000 net income a year earlier.
• Minor pointNine-month operating income declined to $2.978 million from $3.175 million a year earlier.
• Minor pointCash declined to $22.325 million at September 30, 2026, from $23.365 million at December 31, 2025.
• Minor pointQ3 income tax expense increased to $1.371 million from $291,000 a year earlier.

News Explained

At September 30, OptimizeRx reported 20,648,099 common shares issued, versus 20,500,986 at December 31, 2025, while treasury shares were unchanged at 1,741,397; the higher issued count reduces existing holders’ percentage ownership absent offsetting changes.

Argus 15 min delay 8 alerts

-2.46% vs previous close $9.12 last price 2.1x rel. volume Open Argus

Details

Market Reaction – OPRX

-4.7% Trough in 3 min

$9.01 – $9.83 Day Range

$171.78M Mkt Cap at Last Price

On Nov 11, the day this news came out, the latest delayed price for OPRX is 2.46% below the previous close. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $9.12. Relative volume is elevated at 2.1x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Q3 revenue: $21.6 million; down 17% from $26.1 million GAAP net income: $1.2 million versus $0.8 million Adjusted EBITDA: $6.3 million versus $5.1 million +4 more

Q3 revenue

$21.6 million; down 17% from $26.1 million

Q3 2026 versus Q3 2025

GAAP net income

$1.2 million versus $0.8 million

Q3 2026 versus Q3 2025

Adjusted EBITDA

$6.3 million versus $5.1 million

Q3 2026 versus Q3 2025

FY2026 revenue guidance

$87 million to $93 million

Updated fiscal-year outlook

FY2026 adjusted EBITDA guidance

$21 million to $25 million

Unchanged fiscal-year outlook

Debt principal

$9.3 million repaid; $10.4 million outstanding

Repaid since June 30, 2026

Net revenue retention

83% versus 121%

Rolling twelve months ended September 30, 2026 versus 2025

Previous Earnings Reports

1 past event · Latest: Aug 12

Same Type 1 event

1. Aug 12

   Q2 earnings

   24h Move

   +24.7%

   Q2 revenue fell 30%, GAAP net loss was $0.7 million, and FY2026 guidance was reaffirmed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

adjusted ebitda, gaap, net revenue retention, electronic health record

4 terms

adjusted ebitda financial

"Adjusted EBITDA of $6.3 million in Q3 2026 compared to $5.1 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

gaap financial

"GAAP net income of $1.2 million or $0.06 per basic and diluted share"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

net revenue retention financial

"Net revenue retention | 83% | 121%"

Net revenue retention measures how much revenue a company keeps from its existing customers over a set period after accounting for customers who leave, reductions in spending, and any increases from upsells or cross-sells. For investors it shows whether a company can grow sales from the customers it already has—like checking whether a store is making more or less money from its regular shoppers—which signals business health and future revenue durability.

electronic health record technical

"our deeply integrated EHR network with substantial reach"

A digital version of a patient’s medical chart that collects health information — diagnoses, medications, lab results, imaging and doctors’ notes — in one place so authorized clinicians can view and update it. For investors, electronic health records matter because they drive revenue and costs for companies that build, sell or rely on them, influence how quickly care is delivered, and create opportunities (and risks) tied to data access, software updates, regulation and patient privacy. Think of it as an online file cabinet for health that affects how the healthcare system runs and spends money.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Q3 revenue totals $21.6 million
• Q3 net income and adjusted EBITDA of $1.2 million and $6.3 million
• 2026 revenue guidance updated to $87-$93 million; adjusted EBITDA guidance unchanged at $21-$25 million
• Repaid $9.3 million in debt principal since June 30, 2026, reducing current outstanding principal to $10.4 million

WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended September 30, 2026.

Financial Highlights

• Revenue decreased 17% to $21.6 million in Q3 2026, compared to $26.1 million in Q3 2025.
• GAAP net income of $1.2 million or $0.06 per basic and diluted share in Q3 2026, compared to GAAP net income of $0.8 million, or $0.04 per basic and diluted share, in Q3 2025.
• Non-GAAP net income of $3.8 million, or $0.20 per diluted share in Q3 2026, compared to Non-GAAP net income of $3.1 million or $0.16 per diluted share, in Q3 2025. (See *Non-GAAP Measures below)
• Adjusted EBITDA of $6.3 million in Q3 2026 compared to $5.1 million in Q3 2025. (See *Non-GAAP Measures below)
• Operating cash flow was $12.9 million for the nine months ended September 30, 2026 and the Company had cash and cash equivalents of $22.3 million as of September 30, 2026 compared to $23.4 million as of December 31, 2025.
  

Stephen L. Silvestro, OptimizeRx CEO commented, “Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.

“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season. We are seeing expanding opportunities within key accounts, renewed spending in the fourth quarter from a previously significant customer, and indications of pent-up demand as customers execute against their marketing budgets for the 2027 RFP season. We believe these developments, along with our continued focus on strengthening our commercial leadership and broadening our product capabilities, position us to capture additional demand and support future growth.

“More importantly, we believe OptimizeRx is uniquely positioned for the next evolution of healthcare marketing through three fundamental competitive advantages: our proven and increasingly scalable artificial intelligence (AI)-enabled platform, our proprietary healthcare data and solutions that are difficult to replicate or disintermediate, and our deeply integrated EHR network with substantial reach and meaningful barriers to entry. Our Dynamic Audience Activation Platform and expanding AI-enabled audience intelligence capabilities demonstrate the value of these investments, while our partnerships with DeepIntent, The Trade Desk, and PulsePoint are broadening programmatic access to our proprietary network. Together, these initiatives create opportunities to increase network utilization, expand customer reach, and capture a greater share of pharmaceutical marketing budgets. We believe the progress we've made throughout 2026 has established a stronger foundation for sustainable, profitable growth and long-term shareholder value creation.”

	Rolling Twelve Months Ended September 30,
Key Performance Indicators (KPIs)**		2026				2025
	(in thousands, except percentages)
Average revenue per top 20 pharmaceutical manufacturer	$	2,504			$	3,087
Percent of total revenue attributable to top 20 pharmaceutical manufacturers		53	%			56	%
Net revenue retention		83	%			121	%
Revenue per average full-time employee	$	706			$	820

2026 Financial Outlook

The Company is updating its fiscal year 2026 guidance, and now expects revenue of $87 million to $93 million and adjusted EBITDA of $21 million to $25 million.

Conference Call

Date:	Wednesday, November 11, 2026
Time:	4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Toll Free:	1-877-407-9716
International:	1-201-493-6779
Conference ID:	13763502
Call Me:	https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1780405&tp_key=07d90b8ba4
Webcast Replay:	The archived webcast will be on the investor relations section of the OptimizeRx website.

Individual Meeting Invitation

As part of our ongoing investor outreach efforts, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: adsilva@optimizerx.com or dfarrell@lifesciadvisors.com.

*Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow.

Although the Company provides guidance for adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

**Definition of Key Performance Indicators

Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2025 revenue”. We previously used “The top 20 pharma companies by 2024 revenue”. As a result of this change, prior periods have been restated for comparative purposes.

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous 12 months period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by averaging our total number of FTEs at the end of the prior year period and our total FTE headcount at the end of the most recent period.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and direct-to-consumer (DTC) strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. 

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected adjusted EBITDA, the Company’s updated fiscal year 2026 guidance, expected trends in contracted revenue, expanding opportunities within key accounts, renewed customer spending, current strength in the RFP season resulting in growth in contracted revenue, anticipated demand in connection with the 2027 RFP season resulting in customers executing against their marketing budgets, the Company’s investments in commercial leadership and expanded product capabilities positioning the Company to capture additional demand and support future growth, the Company’s competitive advantages, including its AI-enabled platform, proprietary healthcare data and solutions, and integrated EHR network, the DAAP and AI-enabled audience intelligence capabilities, the Company’s partnerships with DeepIntent, The Trade Desk, and PulsePoint broadening programmatic access to the Company’s network, opportunities to increase network utilization, expand customer reach, and capture a greater share of pharmaceutical marketing budgets, the Company’s foundation for sustainable, profitable growth, and long-term shareholder value creation, and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, changes in the timing, amount or renewal of customer contracts and marketing budgets, the ability to successfully develop, commercialize and achieve market acceptance of AI-enabled products and solutions, reliance on third-party partners, including programmatic advertising partners, the Company’s indebtedness, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
adsilva@optimizerx.com

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com

OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)
	September 30, 2026				December 31, 2025
ASSETS	(unaudited)
Current assets
Cash and cash equivalents	$	22,325			$	23,365
Accounts receivable, net of allowance for credit losses of $295 and $260 at September 30, 2026 and December 31, 2025, respectively		25,175				37,752
Taxes receivable		1,653				752
Prepaid expenses and other		3,877				2,846
Total current assets		53,030				64,715
Property and equipment, net		115				106
Other assets
Goodwill		70,869				70,869
Patent rights, net		4,107				4,586
Technology assets, net		5,987				6,870
Customer relationships, net		27,570				29,340
Operating lease right of use assets		397				404
Security deposits and other assets		18				28
Total other assets		108,948				112,097
TOTAL ASSETS	$	162,093			$	176,918
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Current portion of long-term debt	$	1,250			$	4,255
Accounts payable		1,838				1,636
Accrued expenses		5,108				11,591
Revenue share payable		1,552				3,086
Current portion of lease liabilities		232				193
Deferred revenue		502				503
Total current liabilities		10,482				21,264
Non-current liabilities
Long-term debt, net		11,479				21,421
Lease liabilities, net of current portion		185				234
Deferred tax liabilities, net		6,069				5,705
Total liabilities		28,215				48,624
Commitments and contingent liabilities
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2026 or December 31, 2025		—				—
Common stock, $0.001 par value, 166,666,667 shares authorized, 20,648,099 and 20,500,986 shares issued at September 30, 2026 and December 31, 2025, respectively		21				20
Treasury stock, $0.001 par value, 1,741,397 shares held at September 30, 2026 and December 31, 2025		(2	)			(2	)
Additional paid-in-capital		213,083				207,512
Accumulated other comprehensive income		15				—
Accumulated deficit		(79,239	)			(79,236	)
Total stockholders’ equity		133,878				128,294
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	162,093			$	176,918

OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (in thousands, except share and per share data, unaudited)
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Net revenue	$	21,615			$	26,067			$	61,963			$	77,190
Expenses
Cost of revenues, exclusive of depreciation and amortization presented separately below		5,369				8,551				15,097				27,695
Sales and marketing		4,399				5,517				14,656				16,367
General and administrative		3,400				4,169				10,615				12,635
Research and development		2,929				2,723				9,605				9,067
Stock-based compensation		1,784				1,956				5,820				5,002
Depreciation and amortization		1,064				1,080				3,192				3,249
Total expenses		18,945				23,996				58,985				74,015
Income from operations		2,670				2,071				2,978				3,175
Other income (expense)
Interest expense		(177	)			(1,154	)			(2,459	)			(4,053	)
Other income		11				62				87				139
Interest income		62				91				220				269
Total other expenses, net		(104	)			(1,001	)			(2,152	)			(3,645	)
Income (loss) before provision for income taxes		2,566				1,070				826				(470	)
Income tax (expense) benefit		(1,371	)			(291	)			(829	)			582
Net income (loss)	$	1,195			$	779			$	(3	)		$	112
Other comprehensive income, net of tax:
Foreign currency translation adjustment		4				—				15				—
Comprehensive income	$	1,199			$	779			$	12			$	112
Weighted average number of shares outstanding – basic		18,866,127				18,576,199				18,804,756				18,519,665
Weighted average number of shares outstanding – diluted		19,221,763				19,459,877				18,804,756				19,021,905
Income (loss) per share – basic	$	0.06			$	0.04			$	—			$	0.01
Income (loss) per share – diluted	$	0.06			$	0.04			$	—			$	0.01

OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited)
	For the Nine Months Ended September 30,
		2026				2025
OPERATING ACTIVITIES:
Net (loss) income	$	(3	)		$	112
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		3,192				3,249
Stock-based compensation		5,820				5,002
Bad debt expense		42				—
Amortization of debt issuance costs		670				785
Changes in:
Accounts receivable		12,535				5,985
Prepaid expenses and other assets		(1,031	)			(448	)
Accounts payable		202				(119	)
Revenue share payable		(1,534	)			(2,724	)
Accrued expenses and other liabilities		(6,472	)			1,913
Operating lease liabilities		(3	)			15
Deferred tax liabilities		364				—
Taxes receivable and payable		(901	)			(2,065	)
Deferred revenue		(1	)			(78	)
NET CASH PROVIDED BY OPERATING ACTIVITIES		12,880				11,627
INVESTING ACTIVITIES:
Purchases of property and equipment		(68	)			(47	)
Capitalized software development costs		—				(91	)
NET CASH USED IN INVESTING ACTIVITIES		(68	)			(138	)
FINANCING ACTIVITIES:
Cash paid for employee withholding taxes related to the vesting of restricted stock units		(271	)			(188	)
Proceeds from exercise of stock options		21				338
Proceeds from term loan, net of issuance costs		24,298				—
Repayment of long-term debt		(37,915	)			(5,500	)
NET CASH USED IN FINANCING ACTIVITIES		(13,867	)			(5,350	)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		15				—
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(1,040	)			6,139
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		23,365				13,380
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	22,325			$	19,519
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	1,805			$	6,677
Cash paid for income taxes	$	1,375			$	2,094

OPTIMIZERX CORPORATION
RECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES
(in thousands, except share and per share data, unaudited)

This earnings release includes certain financial measures that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures are performance measures that are not defined under GAAP and should be considered in addition to, and not as a substitute for, the most directly comparable GAAP measures. They may also not be comparable to similarly titled measures reported by other companies. Management believes that presenting these non-GAAP financial measures provides useful supplemental information that facilitates comparison of the Company's historical operating results and trends, and offers transparency into how management evaluates the business. Management uses these measures in making financial, operating and planning decisions and in evaluating the Company's performance. Excluding items that management does not consider reflective of ongoing operating results improves the comparability of year-over-year results and helps investors better understand the Company’s underlying performance. These adjustments may include items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance related to executive departures and reductions in force initiatives, shareholder activist related fees, CEO search fees, CMO search fees, other income, estimated income tax impact from adjustments and other items that management believes are not related to the Company’s ongoing performance.

RECONCILIATION of GAAP NET INCOME (LOSS) to NON-GAAP NET INCOME
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Net income (loss)	$	1,195			$	779			$	(3	)		$	112
Depreciation and amortization		1,064				1,080				3,192				3,249
Stock-based compensation		1,784				1,956				5,820				5,002
Severance expenses		697				—				2,441				275
Shareholder activist related fees		—				—				—				451
CEO search fees		—				—				—				225
CMO search fees		80				—				120				—
Other income		(11	)			(62	)			(87	)			(139	)
Amortization of debt issuance costs		35				174				670				785
Estimated income tax impact from adjustments*		(1,009	)			(871	)			(3,362	)			(2,724	)
Non-GAAP net income	$	3,835			$	3,056			$	8,791			$	7,236
Non-GAAP net income per share
Diluted	$	0.20			$	0.16			$	0.46			$	0.38
Weighted average shares outstanding:
Diluted		19,221,763				19,459,877				19,074,626				19,021,905
*Estimated income tax impact from adjustments - consists of current and deferred income tax expense commensurate with the level of adjusted income before income taxes and utilizes an estimated current, blended U.S. and state statutory annual tax rate of 27.6% for all fiscal periods of fiscal 2026 and fiscal 2025. This rate may be subject to change in the future, including as a result of changes in tax policy or tax strategy.

RECONCILIATION of GAAP NET INCOME (LOSS) to ADJUSTED EBITDA
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Net income (loss)	$	1,195			$	779			$	(3	)		$	112
Depreciation and amortization		1,064				1,080				3,192				3,249
Income tax expense (benefit)		1,371				291				829				(582	)
Stock-based compensation		1,784				1,956				5,820				5,002
Severance expenses		697				—				2,441				275
Shareholder activist related fees		—				—				—				451
CEO search fees		—				—				—				225
CMO search fees		80				—				120				—
Other income		(11	)			(62	)			(87	)			(139	)
Interest expense, net		115				1,063				2,239				3,784
Adjusted EBITDA	$	6,295			$	5,107			$	14,551			$	12,377

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is OptimizeRx's updated 2026 financial guidance?

OptimizeRx now expects 2026 revenue of $87 million to $93 million and adjusted EBITDA of $21 million to $25 million. The revenue outlook was lowered, while adjusted EBITDA guidance was unchanged. The company linked the revenue revision to in-year contracted revenue tracking below prior-year levels.

How did OptimizeRx perform in the third quarter of 2026?

OptimizeRx reported $21.6 million in revenue, down 17% year over year, while GAAP net income increased to $1.2 million from $0.8 million. Basic and diluted earnings per share rose to $0.06 from $0.04. Adjusted EBITDA increased to $6.3 million from $5.1 million.

How does OptimizeRx calculate net revenue retention?

OptimizeRx calculates net revenue retention by comparing revenue from clients in the previous 12-month period with revenue from those same clients in the following year. It excludes new client relationships for the most recent year.

Did OptimizeRx change the definition of its top-20 pharmaceutical manufacturer metrics?

OptimizeRx updated its top-20 pharmaceutical manufacturer group to Fierce Pharma's list based on 2025 revenue, replacing the list based on 2024 revenue. Prior periods were restated for comparison. Those manufacturers accounted for 53% of trailing-12-month revenue through September 30, 2026, versus 56% in the comparative period.